Chemistry:Mitizodone

From HandWiki

Mitizodone (developmental code name HEC-113995) is a serotonin reuptake inhibitor and serotonin 5-HT1A receptor partial agonist which is under development for the treatment of major depressive disorder.[1][2][3][4][5] It is being developed by Sunshine Lake Pharma and is being developed towards approval specifically in China.[1][2][3] As of April 2023, no recent development of mitizodone has been reported.[1] The drug has reached phase 3 clinical trials.[1][2][3] Its chemical structure does not yet appear to have been disclosed.[1]

See also

References

  1. 1.0 1.1 1.2 1.3 1.4 "Mitizodone phosphate". 28 April 2023. https://adisinsight.springer.com/drugs/800061157. 
  2. 2.0 2.1 2.2 "Delving into the Latest Updates on Mitizodone Phosphate with Synapse". 23 January 2025. https://synapse.patsnap.com/drug/912f1f0ab0b9422491cdad9ce42cf3b8. 
  3. 3.0 3.1 3.2 "Mitizodone phosphate Drug Profile". 15 October 2021. https://pryzm.ozmosi.com/product/22908. 
  4. "Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review". Innov Clin Neurosci 21 (7–9): 27–47. 2024. PMID 39329027. 
  5. "Current Progress in Targeted Pharmacotherapy to Treat Symptoms of Major Depressive Disorder: Moving From Broad-Spectrum Treatments to Precision Psychiatry". CNS Spectr: 1–45. February 2025. doi:10.1017/S1092852925000094. PMID 39915247.